GVS, one of the world leaders in the supply of filtering solutions for applications in the Healthcare & Life Sciences, Energy & Mobility and Health & Safety sectors, has announced that it has launched the functional activities for the process of listing its ordinary shares on the organized and managed electronic stock market from Borsa Italiana.
In particular, it is expected that the free float required for the purpose of the Listing will be made through a private placement reserved for qualified investors in Italy and institutional investors abroad pursuant to Regulation S of the United States Securities Act of 1933, as subsequently amended, and, in the United States of America, limited to qualified institutional buyers pursuant to Rule 144A of the Securities Act, with the exclusion of those countries in which the Offer is not allowed in the absence of authorization from the competent authorities, in accordance with applicable laws, or exemptions from applicable laws or regulations.
It is also envisaged that the Offer concerns both newly issued Shares – deriving from a capital increase with the exclusion of the option right – and existing Shares, equal to approximately 15% and approximately 85% of the Offer amount, and (ii) includes an option greenshoe.
This composition of the Offer, whose final structure will be determined in the vicinity of its launch, has the objective of providing adequate liquidity of the Shares in theaftermarket.
The Company estimates that the float expected following the outcome of the Offer, including the option greenshoe, will be more than adequate with respect to the minimum requirement requested by Borsa Italiana.
Compatibly with market conditions and subject to obtaining the approvals requested by Consob and Borsa Italiana, the Company believes that the Offer may be initiated during the month of June 2020.
As part of the Offer, Goldman Sachs International and Mediobanca – Banca di Credito Finanziario S.p.A. they act as joint global coordinators is joint bookrunners. Lazard acts as advisor financial position of the Company. Alirahealth acts as independent strategic advisor.
White & Case acts as the Company’s legal advisor, while Clifford Chance acts as the Company’s legal advisor joint global coordinators is joint bookrunners.